Mineralys Therapeutics (MLYS) Cash from Investing Activities (2022 - 2026)

Mineralys Therapeutics has disclosed Cash from Investing Activities across 5 years of filings, most recently posting -$44.9 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$44.9 million, up 51.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$341.8 million (down 538.03% YoY), and the FY2025 annual result was -$389.8 million, down 439.04% from the prior year.
• Cash from Investing Activities came in at -$44.9 million for Q1 2026 at Mineralys Therapeutics, up from -$103.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $83.6 million in Q4 2024 to a low of -$150.5 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is -$42.9 million (2025), against an average of -$33.5 million.
• Across the five-year window, Cash from Investing Activities jumped 1886.65% in 2024 and tumbled 654.3% in 2025, its largest moves.
• Mineralys Therapeutics' Cash from Investing Activities stood at $50.0 million in 2022, then plunged by 116.18% to -$8.1 million in 2023, then surged by 1133.13% to $83.6 million in 2024, then plunged by 223.84% to -$103.5 million in 2025, then jumped by 56.57% to -$44.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$44.9 million (Q1 2026), -$103.5 million (Q4 2025), and -$150.5 million (Q3 2025), per Business Quant data.